Brazil Accelerates Dengue Vaccination as Butantan Moves Up 1.3 Million Doses

Overview

• In a late-February update, Instituto Butantan said 1.3 million Butantan-DV doses will reach the public system in the first half of 2026, bringing total H1 deliveries to 2.6 million and starting with 200,000 this month.
• Rio de Janeiro began administering the single-dose vaccine to primary care workers, with 12,500 doses allocated to 100 units selected for high dengue burden in 2025.
• States expanded rollout plans: Paraíba distributed 13,900 doses and included APS workers up to 59 years, Mato Grosso set out to immunize more than 23,000 health professionals, and Sergipe received 7,900 doses to start next week.
• The national strategy targets about 1.2 million SUS primary-care workers, using a tetravalent vaccine approved for ages 12–59 with reported 74.7% overall efficacy and strong protection against severe disease and hospitalizations.
• Risk assessments by IMDC/Fiocruz/FGV project up to 1.8 million dengue cases in 2026 with concern over DENV-3 spread, while São Paulo reports about 75% of Aedes breeding sites are inside homes, prompting intensified household prevention guidance.